Two secondary pricing regimes, and only one has an anchor

A $101 million bank position sits at the head of this week's LP-led supply, alongside a Dutch pension fund that reached an agreement with BlackRock, and both sellers are pricing off their own balance sheets rather than off the assets inside the positions, which makes institutions moving for reasons that have little to do with the paper counterparties a buyer can read. The week's other secondary deal has no reference attached: Amulet closed a continuation vehicle on US Fertility, and no price was reported. Whether new capital went in above or below the sponsor's mark on the asset is not reported either, leaving the price inside the deal rather than in the market, and leaving the buyers who looked at it and the existing LPs who weighed a roll against an exit working from a figure the sponsor and its lead buyer kept to themselves. Two secondary prints, one week, no published prices in either case, and the interesting difference between them is not disclosure but what a buyer can hold up against the number to judge whether it is fair.

Take the bank position first, because a buyer can underwrite it from the outside: the seller is working off its own balance sheet, and the price it accepts reflects how quickly it wants to be finished with the position, which hands the buyer a reference point in the carrying value on the seller's book and turns an argument about where the price lands relative to par into a negotiation rather than a guess.

A buyer of an LP interest is acquiring exposure to a fund and, unavoidably, a claim on the seller's willingness to be done with it, and the second half of that sentence is where the return gets made in a week like this one. The asset work does not disappear, since nobody takes a portfolio without knowing what is in it, but the question that separates a good purchase from an average one is whether the discount on offer is wider than the seller's situation warrants. A bank that has decided to be finished with a position is a seller a buyer can read.

That is the useful property of balance-sheet supply: the seller's constraint is a second input to price alongside the assets, and reading it well is the difference between buying a discount and buying the going rate.

The distinction has a practical test. If a buyer's own model of the portfolio puts the assets at par and the position clears below it, the gap is the seller's price for relief, and identifying that gap is what the buyer is being paid for. If the model puts the assets below the clearing level, the discount is asset-driven and the seller's urgency is beside the point. Both trades can be good ones, and they do not call for the same diligence.

The Dutch pension fund is direction rather than evidence. The agreement with BlackRock comes with no size and no price attached to it, so it registers as supply in the pipeline instead of a second data point on where LP-led paper clears. One disclosed figure, $101 million, will not settle whether the market is repricing, but it does establish a reference, and a reference is what the week's other deal is missing.

The composition of the supply matters more than its size. A pension fund arriving as a seller is a different event from a fund arriving as a seller, and the buyers who can read an institution's reason to move are the ones positioned to price the trade. Without a size or a price on the BlackRock agreement, the pension leg of the week tells you who is selling rather than what they are getting for it. Useful, and not yet a comparable.

A single-asset continuation vehicle turns on one number, the price at which new capital enters, and there is no second number to check it against. The existing LPs in a structure like that choose between an exit now and a rolled position valued at the entry price the new buyer is paying, so one unpublished figure drives two decisions at once. Neither decision gets tested against a market price, because the entry price is the market price for that deal.

None of that says the fertility price was aggressive, or generous, or anything else. It says the check was unavailable. That is the crux: a discount to par invites an argument, while a sponsor's mark invites assent or absence. A buyer of the bank position can come back with a different view of the assets and a different read of the seller's urgency and negotiate toward a number, while a buyer of a healthcare continuation vehicle can take the price or pass on the deal, and nothing outside the deal helps decide which is right.

There is a reading of the silence that treats it as a warning about where the price landed. The week does not support that reading, and the coverage does not say whether the number was high, low, or unremarkable. What the silence does establish is where the burden sits, with buyers who are underwriting the sponsor's process as much as the asset and who have no published figure to arbitrate between the two.

The counterargument for the unpriced deal has real force. A buyer in a fresh continuation vehicle negotiates from a blank page rather than inheriting a discount somebody else already conceded, and a sponsor that wants a close has reasons to be flexible on terms, but flexibility on terms is not a check on price. The buyer still has to decide whether the entry number is right, and the principal evidence available is the sponsor's view of an asset the sponsor already owns.

The cost of the missing number does not fall on the sponsor; it falls on the LPs who roll and on the buyers who passed, and it falls again on whoever prices the next healthcare continuation vehicle, because the comparable they would ordinarily reach for does not exist.

Should the price surface later, through a subsequent financing or an LP's own reporting, it becomes a reference for the vehicles that follow. Until then, the reference the sector carries forward is one party's view of an asset that party owns, which is a thin thing to price the next deal against.

The practical consequence is two underwriting playbooks running side by side. LP-led paper rewards seller analysis: what the balance sheet needs, how soon, and what discount that justifies. GP-led single-asset paper rewards sponsor analysis: how the mark has moved, who is choosing to roll, and whether the entry price leaves room for an exit. A buyer running one model on both deals will misprice one of them, and which one depends on which model it favors.

What does not carry over between the two is the anchor, and the anchor is what the buyer is really being paid to assess. LP-led work leans on portfolio analysis and a read of the seller's constraint; GP-led single-asset work leans on the asset, the sponsor's record with it, and the terms offered to the LPs who roll.

The bank position is the deal to underwrite and the fertility vehicle is the one to watch. LP-led paper lets a buyer disagree with a price using evidence the buyer can assemble from the seller's own constraint, while the fertility vehicle asks the buyer to accept a price assembled inside the deal and to make that acceptance part of the return.

The question underneath is where price information comes from. A deal with a seller under pressure produces a number other buyers can argue with; a deal whose only reference is the asset's owner produces a number other buyers can only repeat. Both are legitimate secondaries, but only one of them leaves the market better informed than it was on Monday.

The bank's pricing documents will show whether the $101 million position cleared at a discount to par or near it. A discount confirms the balance-sheet read and gives every bank and pension fund holding a comparable position a reason to test the market before year-end; a print near par confines the week's supply story to one seller's timing and leaves the repricing argument without its first piece of evidence.

The answer arrives with the bank's paper and with the next bank that prices a position. The fertility vehicle has already closed without a number, and the next healthcare continuation vehicle will be priced by buyers who had nothing to check this one against.